2 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and ChemotherapyDNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, viral infectious diseaseRecruitingPhase 32026-09-02NCT03394365
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated DiseasesDNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, inborn error of immunity, leiomyosarcoma, lymphatic system disorder, lymphoproliferative syndrome, myomatous neoplasm, neoplasm, sarcoma, viral infectious diseaseActive, not recruitingPhase 22026-07-31NCT04554914